Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Clinical Investigation

• Publication date

  2010-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1172/JCI39964PMID 20484815PMCID PMC2877934
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The hallmarks of cancer

  2012cited by this paper
• A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML.

  2009cited by this paper
• FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation.

  2009cited by this paper
• MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL family

  2009cited by this paper
• Bcl-2 proteins and apoptosis: choose your partner.

  2008cited by this paper
• Small-molecule Bcl-2 antagonists as targeted therapy in oncology

  2008cited by this paper
• Reflecting on 25 years with MYC

  2008cited by this paper
• Distinct thresholds govern Myc's biological output in vivo.

  2008cited by this paper
• Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia.

  2008cited by this paper
• Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers.

  2008cited by this paper
• mTORC1 promotes survival through translational control of Mcl-1

  2008cited by this paper
• c-Myc: linking transformation and genomic instability.

  2008cited by this paper
• Overexpression of N-Myc rapidly causes acute myeloid leukemia in mice.

  2007cited by this paper
• Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia.

  2006cited by this paper
• The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.

  2006cited by this paper
• Neoplasia Driven by Mutant c-KIT Is Mediated by Intracellular, Not Plasma Membrane, Receptor Signaling

  2006cited by this paper
• Promoting apoptosis as a strategy for cancer drug discovery

  2005cited by this paper
• Transcriptional regulation and transformation by Myc proteins

  2005cited by this paper
• c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations.

  2005cited by this paper
• MCLI , a gene expressed in programmed myeloid cell differentiation , has sequence similarity to BCL 2

  2005cited by this paper
• Promoting apoptosis as a strategy for cancer drug discovery

  2005cited by this paper
• Drug therapy for acute myeloid leukemia.

  2005cited by this paper
• Obligate Role of Anti-Apoptotic MCL-1 in the Survival of Hematopoietic Stem Cells

  2005cited by this paper
• More than just proliferation: Myc function in stem cells.

  2005cited by this paper
• MCL-1 expression in B-cell non-Hodgkin's lymphomas.

  2004cited by this paper
• MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors.

  2004cited by this paper
• Defining the temporal requirements for Myc in the progression and maintenance of skin neoplasia

  2004cited by this paper
• Flavopiridol-induced apoptosis is mediated through up-regulation of E2F1 and repression of Mcl-1.

  2003cited by this paper
• Expression of Mcl‐1 in mantle cell lymphoma is associated with high‐grade morphology, a high proliferative state, and p53 overexpression

  2003cited by this paper
• Apoptosis A Link between Cancer Genetics and Chemotherapy

  2002cited by this paper
• Suppression of Myc-Induced Apoptosis in β Cells Exposes Multiple Oncogenic Properties of Myc and Triggers Carcinogenic Progression

  2002cited by this paper
• c-MYC: more than just a matter of life and death

  2002cited by this paper
• Myeloid cell factor-1 is a critical survival factor for multiple myeloma.

  2002cited by this paper
• Apoptosis Triggered by Myc-Induced Suppression of Bcl-XL or Bcl-2 Is Bypassed during Lymphomagenesis

  2001cited by this paper
• Fetal liver myelopoiesis occurs through distinct, prospectively isolatable progenitor subsets.

  2001cited by this paper
• Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1

  2001cited by this paper
• Analysis of C-MYC function in normal cells via conditional gene-targeted mutation.

  2001cited by this paper
• Flavopiridol circumvents Bcl‐2 family mediated inhibition of apoptosis and drug resistance in B‐cell chronic lymphocytic leukaemia

  2001cited by this paper
• Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse.

  1998cited by this paper
• Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions.

  1997cited by this paper
• The proto-oncogene c-myc blocks myeloid differentiation independently of its target gene ornithine decarboxylase.

  1996cited by this paper
• Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.

  1996cited by this paper
• MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2.

  1993cited by this paper
• The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice

  1985cited by this paper

• Ubiquitination Enzymes in Cancer, Cancer Immune Evasion, and Potential Therapeutic Opportunities

  2025cites this paper
• Factors affecting response and resistance to venetoclax in acute myeloid leukemia

  2025cites this paper
• Targeted therapy in acute myeloid leukemia: Resistance and overcoming strategy.

  2025cites this paper
• Regulation of H3K4me3 breadth and MYC expression by the SETD1B catalytic domain in MLL-rearranged leukemia

  2025cites this paper
• MCL1 modulates mTORC1 signaling to promote bioenergetics and tumorigenesis

  2025cites this paper
• Synthesis and Biological Evaluation of Quercetagetin Derivatives as the Inhibitors of Mcl-1 and Bcl-2 Against Leukemia

  2025cites this paper
• Recent Discovery and Development of Inhibitors that Target CDK9 and Their Therapeutic Indications.

  2024cites this paper
• Targeted protein degradation: advances in drug discovery and clinical practice

  2024cites this paper
• Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia

  2024cites this paper
• BCL-2 inhibition in haematological malignancies: Clinical application and complications.

  2024cites this paper
• Fine tuning of the transcription juggernaut: A sweet and sour saga of acetylation and ubiquitination.

  2023cites this paper
• Apoptotic cell death in disease—Current understanding of the NCCD 2023

  2023cites this paper
• Recent Updates in Venetoclax Combination Therapies in Pediatric Hematological Malignancies

  2023cites this paper
• Bifunctional degraders of cyclin dependent kinase 9 (CDK9): Probing the relationship between linker length, properties, and selective protein degradation.

  2023cites this paper
• Advancements in MDM2 inhibition: Clinical and pre-clinical investigations of combination therapeutic regimens

  2023cites this paper
• MCL1 regulates AML cells metabolism via direct interaction with HK2. Metabolic signature at onset predicts overall survival in AMLs’ patients

  2023cites this paper
• Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments

  2023cites this paper
• AKT inhibition sensitizes acute leukemia cells to S63845-induced apoptosis

  2023cites this paper
• Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial

  2022cites this paper
• Concomitant inhibition of FLT3 and MCL-1 in FLT3 mutated Acute Myeloid Leukemia

  2022cites this paper
• Inhibition of Mcl-1 Synergistically Enhances the Antileukemic Activity of Gilteritinib and MRX-2843 in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia

  2022cites this paper
• Splice‐switch oligonucleotide‐based combinatorial platform prioritizes synthetic lethal targets CHK1 and BRD4 against MYC‐driven hepatocellular carcinoma

  2022cites this paper
• c-Myc plays a critical role in the antileukemic activity of the Mcl-1-selective inhibitor AZD5991 in acute myeloid leukemia

  2022cites this paper
• Interplay between protein acetylation and ubiquitination controls MCL1 protein stability

  2021cites this paper
• A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia

  2021cites this paper
• MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies

  2021cites this paper
• Physiological Functions of Mcl-1: Insights From Genetic Mouse Models

  2021cites this paper
• CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents

  2021cites this paper
• MYC protein expression does not correlate with MYC abnormalities detected by FISH but predicts an unfavorable prognosis in de novo acute myeloid leukemia.

  2021cites this paper
• Anti-apoptotic MCL-1 Localizes to the Mitochondrial Matrix and Couples Mitochondrial Fusion to Respiration

  2021influential citation
• Targeting MCL-1 in cancer: current status and perspectives

  2021cites this paper
• The application of BH3 mimetics in myeloid leukemias

  2021cites this paper
• Targeting MCL-1 in hematologic malignancies: Rationale and progress.

  2020cites this paper
• High‐level MYC expression associates with poor survival in patients with acute myeloid leukemia and collaborates with overexpressed p53 in leukemic transformation in patients with myelodysplastic syndrome

  2020cites this paper
• The Role of MYC and PP2A in the Initiation and Progression of Myeloid Leukemias

  2020cites this paper
• Targeting Bcl-2 Family Proteins: What, Where, When?

  2020cites this paper
• Targeting Bcl-2 Proteins in Acute Myeloid Leukemia

  2020cites this paper
• An expert overview of emerging therapies for acute myeloid leukemia: novel small molecules targeting apoptosis, p53, transcriptional regulation and metabolism

  2020cites this paper
• Phase I Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia

  2020cites this paper
• Ancient and conserved functional interplay between Bcl-2 family proteins in the mitochondrial pathway of apoptosis

  2020cites this paper
• Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence

  2020cites this paper
• Saga of Mcl-1: regulation from transcription to degradation

  2020cites this paper
• Glucocorticoids uncover a critical role for ASH2L on BCL-X expression regulation in leukemia cells.

  2019cites this paper
• Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer

  2019cites this paper
• IL1RL1 is dynamically expressed on Cbfb-MYH11+ leukemia stem cells and promotes cell survival

  2019cites this paper
• Myeloid cell leukemia-1 dependence in acute myeloid leukemia: a novel approach to patient therapy

  2019influential citation
• Emerging Therapies for Acute Myelogenus Leukemia Patients Targeting Apoptosis and Mitochondrial Metabolism

  2019influential citation
• Chronic intermittent hypoxia enhances disease progression in myeloma-resistant mice.

  2019cites this paper
• Peptidomimetics: A Synthetic Tool for Inhibiting Protein–Protein Interactions in Cancer

  2019cites this paper
• Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach

  2019cites this paper
• Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia

  2019cites this paper
• Novel Agents for Acute Myeloid Leukemia

  2018cites this paper
• CDK9 inhibitors in acute myeloid leukemia

  2018cites this paper
• Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice

  2018cites this paper
• Glutaminase inhibition in multiple myeloma induces apoptosis via MYC degradation

  2017cites this paper
• Targeting sphingosine kinase 1 in acute myeloid leukemia: translation to clinic.

  2017cites this paper
• BCL-2 family proteins: changing partners in the dance towards death

  2017cites this paper
• Pathogenesis and therapeutic targeting of aberrant MYC expression in haematological cancers

  2017cites this paper
• Function of myeloid cell leukaemia-1 and its regulative relations with hepatocellular carcinoma

  2017cites this paper
• Role of DHX33 in c-Myc-induced cancers

  2017cites this paper
• NAP1L1 regulates NF-κB signaling pathway acting on anti-apoptotic Mcl-1 gene expression.

  2017cites this paper
• Investigating Reptin function in Acute Myeloid Leukaemia

  2017cites this paper
• Targeting apoptosis in acute myeloid leukaemia

  2017cites this paper
• Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies

  2016cites this paper
• BAG3-mediated Mcl-1 stabilization contributes to drug resistance via interaction with USP9X in ovarian cancer.

  2016cites this paper
• Targeting prohibitins induces apoptosis in acute myeloid leukemia cells

  2016cites this paper
• Acid ceramidase is upregulated in AML and represents a novel therapeutic target

  2016cites this paper
• Critical B-lymphoid cell intrinsic role of endogenous MCL-1 in c-MYC-induced lymphomagenesis

  2016cites this paper
• MPT0B169, a novel tubulin inhibitor, induces apoptosis in taxol-resistant acute myeloid leukemia cells through mitochondrial dysfunction and Mcl-1 downregulation

  2016cites this paper
• Re-activation of mitochondrial apoptosis inhibits T-cell lymphoma survival and treatment resistance

  2016cites this paper
• Inhibition of MARCH5 ubiquitin ligase abrogates MCL1-dependent resistance to BH3 mimetics via NOXA

  2016cites this paper
• Preview : Published ahead of advance online publication Re-activation of mitochondrial apoptosis inhibits T cell lymphoma survival and treatment resistance

  2016cites this paper
• Molecular Cell Biology of Apoptosis and Necroptosis in Cancer.

  2016cites this paper
• Loss of a Single Mcl-1 Allele Inhibits MYC-Driven Lymphomagenesis by Sensitizing Pro-B Cells to Apoptosis.

  2016cites this paper
• MYC amplification in multiple marker chromosomes and EZH2 microdeletion in a man with acute myeloid leukemia.

  2015cites this paper
• MYC as therapeutic target in leukemia and lymphoma

  2015cites this paper
• Klinikum rechts der Isar Inhibition of MCL-1 blocks the development of KRAS-driven adenocarcinoma of the lung Enkhtsetseg Munkhbaatar

  2015cites this paper
• Bcl-2 Family: Translational Aspects

  2015cites this paper
• A1/Bcl2a1/BFL1 function in leukocyte development and tumorigenesis

  2015cites this paper
• The BCL-2 protein family, BH3-mimetics and cancer therapy

  2015cites this paper
• MYC-mediated synthetic lethality for treatment of hematological malignancies.

  2015cites this paper
• Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)

  2015cites this paper
• Lessons from gain‐ and loss‐of‐function models of pro‐survival Bcl2 family proteins: implications for targeted therapy

  2015cites this paper
• The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics.

  2015cites this paper
• The TAK1-NF-κB axis as therapeutic target for AML.

  2014cites this paper
• Mcl-1 Ubiquitination: Unique Regulation of an Essential Survival Protein

  2014cites this paper
• PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways

  2014cites this paper
• Regulating cell death at, on, and in membranes.

  2014influential citation
• MYELOID NEOPLASIA The TAK 1-NFk B axis as therapeutic target for AML

  2014cites this paper
• Increased leukocyte survival and accelerated onset of lymphoma in the absence of MCL-1 S159-phosphorylation

  2014cites this paper
• Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets.

  2014cites this paper
• MCL-1 but not BCL-XL is critical for the development and sustained expansion of thymic lymphoma in p53-deficient mice.

  2014cites this paper
• Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53

  2014cites this paper
• Bcl-2 Family and Their Therapeutic Potential

  2014cites this paper
• B-lineage acute lymphoblastic leukemia Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL

  2013cites this paper
• Enhanced stability of Mcl1, a prosurvival Bcl2 relative, blunts stress-induced apoptosis, causes male sterility, and promotes tumorigenesis

  2013influential citation
• MYC oncogene in myeloid neoplasias

  2013cites this paper
• miR-125a/b Regulates the Activation of Cancer Stem Cells in Paclitaxel-resistant Colon Cancer

  2013cites this paper
• IL‐1β inhibits self‐renewal capacity of dormant CD34+/CD38− acute myelogenous leukemia cells in vitro and in vivo

  2013influential citation
• MCL-1ES Induces MCL-1L-Dependent BAX- and BAK-Independent Mitochondrial Apoptosis

  2013cites this paper